BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 34,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 34,000 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00. Following the completion of the sale, the chief executive officer owned 519,209 shares in the company, valued at approximately $51,194,007.40. This trade represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Trading Down 2.6%

Shares of BNTX stock traded down $2.60 on Friday, hitting $96.06. The stock had a trading volume of 1,150,292 shares, compared to its average volume of 1,102,362. The company’s 50 day moving average price is $97.29 and its 200-day moving average price is $94.92. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The firm has a market capitalization of $24.29 billion, a P/E ratio of -12.27 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s revenue was down 59.5% compared to the same quarter last year. During the same quarter last year, the business earned ($1.60) earnings per share. Analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Canaccord Genuity Group reduced their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, UBS Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $126.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Larson Financial Group LLC lifted its holdings in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares in the last quarter. AlphaCentric Advisors LLC grew its stake in shares of BioNTech by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock valued at $499,000 after acquiring an additional 305 shares in the last quarter. USS Investment Management Ltd grew its stake in shares of BioNTech by 1.2% during the first quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock valued at $2,854,000 after acquiring an additional 382 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of BioNTech in the second quarter worth about $39,000. Finally, Marks Group Wealth Management Inc boosted its holdings in BioNTech by 16.0% in the first quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock valued at $307,000 after purchasing an additional 476 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.